When was Flexion Therapeutics founded?

Flexion Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Flexion Therapeutics located?

Flexion Therapeutics is headquartered in Woburn, United States. It is registered at Parsippany, New Jersey.

How many employees does Flexion Therapeutics have?

As of Aug 31, 2026, the latest employee count at Flexion Therapeutics is 24.

Is Flexion Therapeutics a funded company?

Flexion Therapeutics is a funded company, having raised a total of $62M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 16, 2009.

How much is Flexion Therapeutics worth?

The last known valuation of Flexion Therapeutics was $***** as of Oct 11, 2021.

When was the latest funding round of Flexion Therapeutics?

Flexion Therapeutics' latest funding was a $***** Post IPO round on May 2017, with participation from 0 investor.

Where does Flexion Therapeutics rank among its competitors?

Flexion Therapeutics ranks 383rd amongst 2837 active competitors, of which 928 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Flexion Therapeutics?

Flexion Therapeutics' top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Flexion Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Q: Is Flexion Therapeutics an acquired company?

Flexion Therapeutics got acquired by Pacira on Oct 11, 2021.

Flexion Therapeutics is an acquired company based in Woburn (United States), founded in 2007 by Neil Bodick. It operates as a Developer of therapies for the treatment of musculoskeletal disorders. Flexion Therapeutics has raised $62M in funding from Versant Ventures and Novo Holdings, with last known valuation of $*****. The company has 2837 active competitors, including 928 funded and 702 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

Developer of therapies for the treatment of musculoskeletal disorders. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapies. Their lead program, FX006, is an intra-articular sustained-release steroid injectable for patients with moderate to severe osteoarthritis (OA) pain. They also have two additional product candidates FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Website: flexiontherapeutics.com
Social
Email ID: *****@flexiontherapeutics.com
Registered Address: Parsippany, New Jersey

Key Metrics

Founded Year

2007

Location

Woburn, United States

Stage

Acquired

Total Funding

$62M in 4 rounds

Latest Funding Round

Post IPO, May 2017, $*****

Last Known Valuation

$***** as on Oct 11, 2021

Investors

Versant Ventures & 6 more

Ranked

383^rd among 2837 active competitors

Employee Count

24 as on Aug 31, 2026

Similar Companies

Heron Therapeutics & 403 more

Exit Details

Acquired by Pacira (Oct 11, 2021)

View Flexion Therapeutics' full profile

Flexion Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FLEXION THERAPEUTICS INC CIN: 1419600 , United States, Active		$50M - $100M (As on Dec 31, 2020)	-	-
Pacira Pharmaceuticals, Inc. CIN: 330387911 , United States, Active	Dec 26, 999	-	777 (As on Dec 31, 2024)	-

Flexion Therapeutics got acquired by Pacira on Oct 11, 2021 at an acquisition amount of $*****.

Click here to take a look at Flexion Therapeutics's acquisition in detail

Flexion Therapeutics has raised a total funding of $62M over 4 rounds. Its first funding round was on Oct 16, 2009. Flexion Therapeutics has 7 institutional investors.

Here is the list of recent funding rounds of Flexion Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 2017	5387021	Post IPO	8028786	3958538	5291335	7351972
Apr 2017	3772462	Post IPO	6731364	3957086	6381254	9082797
Dec 04, 2012	8094551	Series B	4652842	8005918	Novo Holdings	5AM Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Flexion Therapeutics's funding rounds and investors

The founders of Flexion Therapeutics is Neil Bodick.

Here are the details of Flexion Therapeutics' key team members:

Neil Bodick: Former Co-Founder & CSO of Flexion Therapeutics and founder of 1 other company.
Contact Info: 1 email address

View details of Flexion Therapeutics's Founder profiles and Board Members

Flexion Therapeutics' employee count trend

Flexion Therapeutics has 24 employees as of Aug 26. Here is Flexion Therapeutics's employee count trend over the years:

Employee count trend for Flexion Therapeutics

Uncover Flexion Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Flexion Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Flexion Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
383rd	Flexion Therapeutics 2007, Woburn (United States), Acquired	Developer of therapies for the treatment of musculoskeletal disorders	$62M	Versant Ventures, Novo Holdings & 5 others	53/100